

LISTING OF THE CLAIMS

1-18. **(Cancelled)**

19. **(Previously Presented)** A purified monoclonal antibody, or epitope-binding fragment thereof, which binds to a gp120 epitope bound by monoclonal antibody 5B3, produced by a hybridoma with ATCC accession number CRL 10515, wherein said antibody or fragment thereof blocks CD4/gp120 binding and reduces reverse transcriptase activity *in vitro*.

20. **(Previously Presented)** A monoclonal antibody, selected from the group consisting of monoclonal antibodies 5B3, 6E10, and 13H8, produced by hybridomas with ATCC accession nos. CRL 10515, CRL 10514, and CRL 10510, respectively.

21. **(Cancelled)**

22. **(Previously Presented)** The monoclonal antibody of claim 20, wherein said monoclonal antibody is conjugated to a toxin.

23-26. **(Cancelled)**

27. **(Previously Presented)** The purified antibody or epitope-binding fragment thereof of claim 19 that is covalently bound to a detectable marker or a water insoluble matrix.

28. **(Previously Presented)** The purified antibody or epitope-binding fragment thereof of claim 19 that comprises monoclonal antibody 5B3, produced by a hybridoma with ATCC accession number 10515.

29. **(Previously Presented)** A hybridoma or cell culture comprising an antibody, or epitope-binding fragment thereof, which binds to a gp120 epitope bound by monoclonal antibody 5B3, produced by a hybridoma [hybridomas] with ATCC accession number 10515, wherein said antibody or fragment thereof blocks CD4/gp120 binding and reduces reverse transcriptase activity *in vitro*.

30. **(Previously Presented)** A hybridoma selected from the group consisting of hybridomas with ATCC accession numbers CRL 10515, CRL 10514, CRL and 10510.

31. **(Previously Presented)** The monoclonal antibody of claim 20, wherein said monoclonal antibody is covalently bound to a detectable marker or a water insoluble matrix.

32. **(Previously Presented)** The purified antibody or epitope-binding fragment thereof of claim 19 that is conjugated to a toxin.

33. **(Previously Presented)** The monoclonal antibody of claim 20, wherein said monoclonal antibody comprises monoclonal antibody 6E10, produced by a hybridoma with ATCC accession number 10514.

34. **(Previously Presented)** The monoclonal antibody of claim 20, wherein said monoclonal antibody comprises monoclonal antibody 13H8, produced by a hybridoma with ATCC accession number 10510.

35. **(Previously Presented)** The hybridoma of claim 30, wherein the hybridoma has ATCC accession no. 10514.

36. **(Previously Presented)** The hybridoma of claim 30, wherein the hybridoma has ATCC accession no. 10510.

37. **(Previously Presented)** A monoclonal antibody, selected from the group consisting of monoclonal antibodies 10D8, 10F6 and 11G5, produced by hybridomas with ATCC accession nos. CLR 10513, CLR 10512, and CLR 10511, respectively.

38. **(Previously Presented)** The monoclonal antibody of claim 37, wherein said monoclonal antibody is conjugated to a toxin.

39. **(Previously Presented)** The monoclonal antibody of claim 37, wherein said monoclonal antibody is covalently bound to a detectable marker or a water insoluble matrix.

40. **(Previously Presented)** A hybridoma selected from the group consisting of hybridomas with ATCC accession numbers CRL 10513, CRL 10512, CRL and 10511.